Evergreen Capital Management LLC Boosts Stake in Johnson & Johnson $JNJ

Evergreen Capital Management LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,507 shares of the company’s stock after buying an additional 5,880 shares during the quarter. Evergreen Capital Management LLC’s holdings in Johnson & Johnson were worth $9,701,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after acquiring an additional 6,332 shares during the last quarter. United Bank grew its holdings in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after purchasing an additional 4,876 shares during the last quarter. Cookson Peirce & Co. Inc. purchased a new position in Johnson & Johnson in the 1st quarter worth about $208,000. EverSource Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 10.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 19,646 shares of the company’s stock valued at $3,258,000 after buying an additional 1,863 shares in the last quarter. Finally, Forvis Mazars Wealth Advisors LLC grew its stake in Johnson & Johnson by 37.6% in the 1st quarter. Forvis Mazars Wealth Advisors LLC now owns 58,656 shares of the company’s stock worth $9,728,000 after acquiring an additional 16,019 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on JNJ shares. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Stifel Nicolaus raised their price objective on Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Finally, Royal Bank Of Canada boosted their price target on Johnson & Johnson from $209.00 to $230.00 and gave the stock an “outperform” rating in a research note on Thursday. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $207.55.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $211.65 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $212.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company’s fifty day moving average price is $196.09 and its 200 day moving average price is $177.25. The stock has a market capitalization of $509.93 billion, a P/E ratio of 20.43, a P/E/G ratio of 2.36 and a beta of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The business had revenue of $24.02 billion during the quarter. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.